COSELA shields helping to protect a neutrophil and red blood cell while a chemotherapy arrow targets cancer cells

To decrease the incidence of chemotherapy-induced myelosuppression in patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen

For extensive-stage small cell lung cancer (ES-SCLC)

SPARE THE MARROW. SPEAR THE TUMOR.

COSELA HELPS PROTECT AGAINST myelosuppression, while chemotherapy targets cancer cells

COSELA™ (trilaciclib) helps protect hematopoietic stem and progenitor cells (HSPCs), the source of blood cell lineages, including neutrophils, red blood cells, and platelets

The First and Only Proactive Multilineage Myeloprotection Therapy

In the Pivotal Study in 1st-Line ES-SCLC, COSELA administered before an etoposide/carboplatin + atezolizumab (E/P/A) regimen resulted in1:

REDUCED INCIDENCE AND DURATION OF SEVERE NEUTROPENIA

Primary Endpoints: 1.9% vs 49.1% (P<0.0001) and 0 days vs 4 days (P<0.0001) with and without COSELA, respectively*

NUMERICALLY LOWERED INCIDENCE OF GRADE 3/4 ANEMIA AND RBC TRANSFUSIONS

Secondary Endpoints: 19% vs 28% and 13% vs 21% with and without COSELA, respectively

REDUCED INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA

Secondary Endpoint: 1.9% vs 37.7% with and without COSELA (P=0.0026)

REDUCED RATE OF CHEMOTHERAPY DOSE REDUCTIONS

Secondary Endpoint: 2.1 vs 8.5 with and without COSELA (P=0.0195)§

* Multiplicity-adjusted P values. Adjusted relative risk (aRR) 0.038 (95% CI, 0.008, 0.195) and mean difference -3.6 (95% CI, -4.9, -2.3), respectively. Duration evaluated in Cycle 1.
aRR 0.663 (95% CI, 0.336, 1.310) and aRR 0.642 (95% CI, 0.294, 1.404). Red blood cell (RBC) transfusions measured on/after 5 weeks. Grade 3/4 anemia defined as Grade 3/4 decreased hemoglobin.
Raw one-sided P value not adjusted for multiplicity. aRR 0.053 (95% CI, 0.008, 0.356). Platelet endpoint results were not consistent across studies. See Study 2. See Study 3.
§ Raw one-sided P value not adjusted for multiplicity. Rate of all-cause dose reductions, events per 100 cycles. aRR 0.242 (95% CI, 0.079, 0.742).

Standard-of-care supportive interventions, including RBC and platelet transfusions, were allowed per investigator discretion throughout the entire treatment period. Primary prophylaxis with granulocyte colony-stimulating factors (G-CSFs) and use of erythropoiesis stimulating agents (ESAs) were prohibited in Cycle 1 of induction, although therapeutic G-CSF was allowed in all cycles. More patients in the E/P/A regimen arm without COSELA received G-CSF Administration (47.2% vs 29.6%, aRR 0.646 [95% CI, 0.403, 1.034]) and had ESA use (11% vs 6%, aRR 0.529 [95% CI, 0.145, 1.927]) vs with COSELA, respectively.

See Study Design >

See Multilineage Efficacy >
Neutrophil cell
Neutrophil cell Neutrophil cell Neutrophil cell 96%REDUCTION IN INCIDENCE OF SEVERE NEUTROPENIA
Red blood cell Red blood cell GRADE 3/4 ANEMIA INCIDENCE:19% WITH COSELA vs 28% WITHOUT#
Red blood cell
Platelet
Platelet Platelet GRADE 3/4 THROMBOCYTOPENIA INCIDENCE:1.9% WITH COSELA vs 37.7% WITHOUT††
DOSE REDUCTIONS RATE‡‡8.5 WITHOUTCOSELA2.1 WITHCOSELA DOSE REDUCTIONS RATE‡‡2.1 WITHCOSELA8.5 WITHOUTCOSELA

DATA FROM THE PIVOTAL STUDY (E/P/A)1:

REDUCED INCIDENCE AND DURATION OF SEVERE NEUTROPENIA

PRIMARY ENDPOINTS

  • 96% reduction in the incidence of severe neutropenia with COSELA (1.9% vs 49.1%; P<0.0001)
  • 0 days of severe neutropenia with COSELA vs 4 days without COSELA (P<0.0001)
  Multiplicity-adjusted P values.
aRR 0.038 (95% CI, 0.008, 0.195).
Mean difference -3.6 (95% CI, -4.9, -2.3). Duration evaluated in Cycle 1.
See Pivotal Study Multilineage Data >

NUMERICALLY LOWERED INCIDENCE OF GRADE 3/4 ANEMIA AND RBC TRANSFUSIONS

SECONDARY ENDPOINTS

  • The incidence of Grade 3/4 anemia was 19% with COSELA vs 28% without COSELA#
  • The incidence of red blood cell (RBC) transfusions was 13% with COSELA vs 21% without COSELA**
# aRR 0.663 (95% CI, 0.336, 1.310). Grade 3/4 anemia defined as Grade 3/4 decreased hemoglobin.
** aRR 0.642 (95% CI, 0.294, 1.404). RBC transfusions measured on/after 5 weeks.
See Pivotal Study Multilineage Data >

REDUCED INCIDENCE OF GRADE 3/4 THROMBOCYTOPENIA

SECONDARY ENDPOINT

  • The incidence of Grade 3/4 thrombocytopenia was 1.9%
    with COSELA vs 37.7% without COSELA (P=0.0026)††
†† Raw one-sided P value not adjusted for multiplicity. aRR 0.053 (95% CI, 0.008, 0.356). Platelet endpoint results were not consistent across studies. See Study 2. See Study 3.
See Pivotal Study Multilineage Data >

REDUCED RATE OF CHEMOTHERAPY DOSE REDUCTIONS

SECONDARY ENDPOINT

  • The reduced rate of chemotherapy dose reductions (events per 100 cycles) was 2.1 with COSELA vs 8.5 without COSELA (P=0.0195)‡‡
‡‡ Raw one-sided P value not adjusted for multiplicity. aRR 0.242 (95% CI, 0.079, 0.742).
See Dose Reductions/Delays Data >

INTEGRATED SAFETY ACROSS STUDIES

The most common adverse reactions (≥10%) were fatigue, hypocalcemia, hypokalemia, hypophosphatemia, aspartate aminotransferase increased, headache, and pneumonia.

See Safety Data >

INDICATION: COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).

THE FIRST & ONLY MYELOPROTECTION THERAPY

COSELA helps protect hematopoietic stem and progenitor cells (HSPCs), the source of multiple blood cell lineages, including neutrophils, red blood cells, and platelets. Watch the COSELA mechanism of action (MOA) video to learn about the proactive and multilineage MOA.

Additionally, find key insights from a leading medical oncologist.

Explore the MOA >